Apply Now

News » Archives » April 2017

Warren Center faculty member presents at the Solutions for Drug-Resistant Infections Conference (SDRI 2017)

Author: Richard Taylor

Professsor Marv Miller presented the seminar, “Conjugation of an acinetobacter selective sideophore to Daptomycin generates a sideromycin with potent activity against acinetobacter baumannii” at the Antimicrobial Drug Discovery Symposium at the Solutions for Drug-Resistant Infections (SDRI) conference in Brisbane, Australia, April 3-5. SDRI 2017 brought together leading scientific, medical and

Co Add500

industry experts to discuss new solutions to the global challenge of drug-resistant pathogens.

The Gram-negative pathogens, such as A. baumannii, have become a significant worldwide threat due to their resistance to many current antibiotics. Read More

2017 Research Like a Champion Award Winners

Author: Jenna Bilinski

Rlac Logo Web1

Congratulations to the 2017 Research Like a Champion program winners. This was the most successful year for the program with the highest number of applicants and the most innovative projects. 

Students: Marwa Asem and Carlysa Oyama

Project Title: Tunneling Nanotubes in Cancer: When Your Healthy Cells Betray Your Body

Mentor: M. Sharon Stack, Ann F. Dunne and Elizabeth Riley Director of Harper Cancer Research Institute

  Read More

Funding Scientific Research fuels Job Creation

Author: Brandi Klingerman

Sparking Economic Growth

The University of Notre Dame is highlighted in a new report on the importance of scientific research to economic growth.

The study, which was conducted by The Science Coalition, identifies more than 100 companies that exist due to funding received by academic researchers from federal government agencies, including the Department of Agriculture, Department of Energy, National Institutes of Health, National Institute of Standards and Technology, and National Science Foundation. Read More

Notre Dame’s Genomics and Bioinformatics Core Facility Acquires New Equipment

Author: Brandi Klingerman

Illuminapic

The new system for high-throughput sequencing supports health and environmental research

From cancer to vector-borne diseases, and from drug development to monitoring invasive species, DNA sequencing is vital to the research being done at the University of Notre Dame. To support these research efforts, the Genomics and Bioinformatics Core Facility (GBCF) has acquired an illumina NextSeq 500 Sequencing System, for next generation high-throughput genomics sequencing. Read More

Kasturi Haldar wins 2017 Ganey Award for community-based research

Author: JP Shortall

 

Haldar Profile

Professor Kasturi Haldar has received the 2016 Rodney F. Ganey, Ph.D., Community-Based Research Award for a project that has helped improve rare disease recognition and treatment in northern Indiana. The award is a $5,000 prize presented annually to a regular faculty member at the University of Notre Dame who has completed at least one research project that addresses a need within South Bend or the surrounding area. Haldar is a molecular cell biologist and the Rev. Julius Nieuwland Professor of Biological Sciences and Parsons-Quinn director of the Boler-Parseghian Center for Rare and Neglected Diseases at the University of Notre Dame. Read More

Research Supported by the Ara Parseghian Medical Research Fund Reaches Important Milestone

Author: Sean Kassen

Parseghianchildren 250

Niemann-Pick Type C (NPC) disease is a rare, genetic, cholesterol storage disorder that is always fatal, primarily striking children before or during adolescence, and it has a long history with the Notre Dame family. In 1994, Notre Dame alumni Cindy and Michael Parseghian founded the Ara Parseghian Medical Research Foundation after they learned that three of their four children were diagnosed with NPC disease. The foundation is named after Ara Parseghian, the legendary Notre Dame Football coach and the children’s grandfather.

On March 15, 2017, Vtesse, Inc. (recently acquired by Sucampo Pharmaceuticals, Inc.) announced full enrollment in the Phase 2b/3 clinical trial of VTS-270, a well-characterized complex mixture of 2-hydroxypropyl-b-cyclodextrin (HPβCD) with a specific compositional fingerprint that distinguishes it from other HPβCD mixtures, in Niemann-Pick Type C1 (NPC) disease. The investigational drug candidate showed promise in pre-clinical and early clinical studies for NPC disease. Read More

Notre Dame Professor Siyuan Zhang wins CTSI grant

Author: Cliff Djajapranata

 

Siyaunzhang 250

Siyuan Zhang, Nancy Dee Assistant Professor of Cancer Research, Assistant Professor of Biological Sciences and affiliated member of Harper Cancer Research Institute at the University of Notre Dame, recently won a grant from the Indiana Clinical and Translational Sciences Institute (CTSI). Awarded Pilot Funding for Research Use of Core Facilities, Zhang is planning on using his funding to learn more about brain metastasis in cancer patients. The award was designed to promote the use of technologies and knowledge made available by Indiana CTSI-designed cores available at partner institutions. Read More

Tuberculosis Research Sheds Light on Disease-related Protein

Author: Brandi Klingerman

Champion Patricia

The WHO names Tuberculosis (TB) as one of the top 10 causes of death worldwide and over 95 percent of those deaths occur in low- and middle-income countries. To improve the global health community’s understanding of TB and provide information that could help treat it, Notre Dame researchers have developed a new strain of the bacteria along with a new method to better study this deadly disease.  Read More